Brief: Sorrento Acquires A Majority Ownership In Zhengzhou Fortune Bioscience
17/02/2022 18:04
Feb 17 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO ANNOUNCES THAT IT HAS ACQUIRED A MAJORITY
OWNERSHIP IN
DIAGNOSTIC MANUFACTURER ZHENGZHOU FORTUNE BIOSCIENCE IN RESPONSE
TO INCREASING WORLDWIDE DEMAND FOR COVISTIX™
* SORRENTO THERAPEUTICS INC - HAS INVESTED AND BECOMES A
MAJORITY
OWNER WITH AN OPTION TO ACQUIRE 100% OF FORTUNEBIO
Source text for Eikon: ID:nGNX1xdRVW
Further company coverage: SRNE.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20